• About Us
  • News
  • Publications
  • Events
  • Careers
  • Contact
ProMabLogoProMabLogoProMabLogoProMabLogo
  • Login
  • 0 Items ($0.00)
    My Cart 1
  • Login
  • 0 Items ($0.00)
    My Cart 1
  • Top Sellers
    • CD19scFv-BEAM-CD28-CD3ZCD19scFv-BEAM-CD28-CD3ζ
    • CAR-T_Cell_MediumCAR-T Cell Medium
    • CD28-CD3_PM-T-Cell_Activation__Expansion_Beads_editCD28-CD3 Activation Beads
    • Cancer._Stem_PremiumCancer Stem Premium
    • P16_Antibody-v2P16 Antibody
  • Products
    • COVID19_8-04-2020COVID-19
    • primary-antibodyPrimary Antibody
      • Polyclonal Antibodies
      • Monoclonal Antibodies
    • Protein_IconFull-Length Protein
      • Recombinant Proteins
      • Natural Proteins
      • COVID-19 Research Products
    • CAR-T_iconCAR-T/CAR- NK
      • CAR-T cells
      • CAR-NK cells
      • T cell Activation Beads
      • Peripheral Blood Monocytes
    • Hempotological_products_IconHematological Products
      • Primary Cells
      • Non-Transduced T cells
      • Cell Media
      • Freezing Media
    • Icon_Product_mRNP_Lipid Nanoparticle_5_02_2022_finalmRNA-Lipid Nanoparticles
      • mRNA Products
      • LNP Products
    • stem-cell-iconCancer Stem Cells
      • Cancer Stem Cell Media
      • Hepatocellular Carcinoma (HCC)
      • Kidney Cancer
      • Ovarian Adenocarcinoma
      • Pancreatic Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
      • Lung Cancer Non-Small Cell (NSCLC)
      • Bladder Cancer
      • Breast Carcinoma
      • Colorectal Cancer
      • Glioblastoma
      • Head and Neck (H&N) Carcinoma
  • Services
    • v1-_Licensing_and_Distributing_CAR_Technology_7_22_2019_edit-1Licensing and Distributing CAR Technology
    • No_circles_-v2_Engineered_Cell_Lines-7_22_2019_finalCAR-T/CAR-NK Development
      • Custom CAR-T Cell Development
      • Custom CAR-NK Cell Development
      • Custom CAR-Macrophage Cell Development
      • Custom Gamma Delta T Cell Development
      • mRNA-LNP Gene Delivery
      • Lentivirus Production
      • Animal Research
      • Cancer Stem Cell Services
    • Cell_Based_Assay1_lastCell Based Assays
      • Flow Cytometry Services –
      • T Cell Specificity Assay
      • T Cell Activation & Proliferation Assay
      • Responsive T Cell Trafficking Assay
      • Cytokine Response Assay
      • Macrophage Polarization Assay
      • DC Migration Assay
    • Icon_ Services_mRNP_Lipid Nanoparticle_5_02_2022_finalmRNA-Lipid Nanoparticles
      • mRNA-LNP Gene Delivery
    • No_circles_-v3-Custom_Antibody_Engineering_7_22_2019_finalAntibody Engineering Services
      • Mouse Monoclonal Antibodies
      • Rabbit Monoclonal Antibodies
      • Human Monoclonal Antibodies
      • Recombinant Antibodies
      • Bispecific Antibodies
      • Antibody Humanization
      • Rabbit Polyclonal Antibodies
      • Hybridoma Sequencing
      • Antibody Production
    • No_circles_-v4-Protein_Expression_Services_7_22_2019_finalProtein Expression Services
      • E.coli Expression
      • Baculovirus Expression
      • Mammalian Expression
      • Stable Cell Line Development
      • Peptide Synthesis
      • Gene Synthesis Services
  • Protocols & Troubleshooting
    • Protocols
    • Technology
    • Troubleshooting
    • FAQ
AACR Annual Meeting 2018
April 10, 2018
Expanding our CRO capabilities to now include TCR and BCR profiling
April 10, 2018

Helix BioPharma Corp Signs Collaboration Agreement With Promab Biotechnologies To Co-Develop CAR-T For Hematological Malignancies

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the completion of the collaboration agreement with ProMab Biotechnologies, Inc. (“ProMab”) to develop novel antibody and chimeric antigen receptor T-cell therapy (“CAR-T”) for particular hematological malignancies (i.e. multiple myeloma).

The Company had previously announced the signing of a binding letter of intent (“LOI”) with ProMab to develop CAR-T for various hematological malignancies and solid tumors. Today the Company announced the signing of the first scientific collaboration to co-develop a cell-based therapy for Multiple Myeloma. The Multiple Myeloma co-development program will aim to complete all necessary work with the objective of filing for a first-in-human study by early 2019. Under the collaboration agreement, Helix retains commercial rights for this CAR-T in Canada and Europe and is currently in the process of reviewing what expansion criteria may be required at its European operations in Poland to facilitate commercialization.

In the meantime, Helix’s core team continues to prioritize the Company’s DOS47 drug development program, particularly its clinical L-DOS47 program and its pre-clinical V-DOS47 pre-clinical program.

 

Share

Sign up for news & promotions:

Products

  • Antibodies
  • Proteins
  • CAR T/NK Cells
  • Cell Lines
  • Cell Culture

Services

  • CAR-T/CAR-NK Development
  • Custom Antibodies
  • Synthesis and Expression
  • Clinical Research

Resources

  • Protocols
  • Technology
  • Troubleshooting
  • FAQ

Promab Biotechnologies

  • Promotions
  • About
  • News
  • Publications
  • Careers
  • Contact Us
Copyright © ProMab 2022 All Rights Reserved ProMab Biotechnologies, Inc. | 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USA | Email: info@promab.com